J3301 HCPCS code: Injection, triamcinolone acetonide, not otherwise specified, 10 mg
J3301 is the HCPCS Level II code for injection, triamcinolone acetonide, not otherwise specified, 10 mg. In 2024 Medicare paid an average of $0.72 per service for J3301 across 18,042,461 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 16 per day on outpatient hospital claims. Medicare volume rose 8% from 2022 to 2024 (16,683,786 to 18,042,461 services). In 2024, about 106,517 clinicians billed Medicare for J3301 for 2,222,767 beneficiaries; Florida, California, Texas accounted for 23% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 1991-01-01 |
| Last action effective | 2009-01-01 |
Who bills J3301 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 106,517 |
| Medicare beneficiaries | 2,222,767 |
| States with claims | 57 |
| Share of services in top 3 states (Florida, California, Texas) | 23% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J3301, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 16,683,786 | 2,194,525 | $1.13 | $0.85 |
| 2023 | 17,389,845 | 2,201,890 | $1.06 | $0.80 |
| 2024 | 18,042,461 | 2,222,767 | $0.97 | $0.72 |
States with the most J3301 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 1,675,907 | $0.74 |
| California | 1,303,962 | $0.74 |
| Texas | 1,178,020 | $0.71 |
| Pennsylvania | 966,658 | $0.73 |
| North Carolina | 890,080 | $0.72 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 16 | Prescribing Information |
| practitioner claims | 16 | Prescribing Information |
Medicare policy articles for this code
- A57114: Billing and Coding: Trigger Point Injections (First Coast Service Options, Inc. (MAC - Part B))
- A57751: Billing and Coding: Trigger Point Injections (Novitas Solutions, Inc. (MAC - Part A, MAC - Part B))
Covered diagnoses (2 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| M79.12 | Myalgia of auxiliary muscles, head and neck | 2 |
| M79.18 | Myalgia, other site | 2 |
What changed for J3301
- 1991-01-01: J3301 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3301?
J3301 is the HCPCS Level II code for injection, triamcinolone acetonide, not otherwise specified, 10 mg. Short descriptor: "Triamcinolone acet inj nos".
How much does Medicare pay for J3301?
In 2024, the average Medicare payment was $0.72 per service (average allowed $0.97).
Does Medicare cover J3301?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
Which diagnoses support coverage for J3301?
Medicare policy articles that cite J3301 list 2 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include M79.12 (Myalgia of auxiliary muscles, head and neck), M79.18 (Myalgia, other site). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J3301 can be billed per day?
16 on outpatient hospital claims; 16 on practitioner claims (NCCI medically unlikely edits).
Related J33 codes
- J3300 — Injection, triamcinolone acetonide (triesence), preservative free, 1 mg
- J3302 — Injection, triamcinolone diacetate, per 5 mg
- J3303 — Injection, triamcinolone hexacetonide, per 5 mg
- J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
- J3305 — Injection, trimetrexate glucuronate, per 25 mg
- J3310 — Injection, perphenazine, up to 5 mg
- J3315 — Injection, triptorelin pamoate, 3.75 mg
- J3316 — Injection, triptorelin, extended-release, 3.75 mg
- J3320 — Injection, spectinomycin dihydrochloride, up to 2 gm
- J3350 — Injection, urea, up to 40 gm
- J3355 — Injection, urofollitropin, 75 iu
- J3357 — Ustekinumab, for subcutaneous injection, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3301
- Watch J3301 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3301
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.